Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug ...

Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.

Whoopi Goldberg issued a stern warning to her fans, "Do not look at this!" after a problem was brought to her attention.

Goldberg said the company "melded" a 'CBS News Sunday Mornings' appearance from her to sell “bad weight loss drugs." ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.